1. ScholarBank@NUS

ONG PEI SHI

rp10093

Collaboration Map View Statistics Email Alert RSS Feed

Profile

Full Name
ONG PEI SHI
Variants
Ong, P.S.
Ong, P.-S.
 
Main Affiliation
 
Faculty
 
Email
phaops@nus.edu.sg
 

Publications

Results 1-15 of 15 (Search time: 0.013 seconds).

Issue DateTitleAuthor(s)
130-Jan-2013A miniaturized flow-through cell to evaluate skin permeation of endoxifenMah, C.S.; Kochhar, J.S.; Ong, P.S. ; Kang, L. 
210-Oct-2016A novel combinatorial strategy using Seliciclib (R) and Belinostat (R) for eradication of non-small cell lung cancer via apoptosis induction and BID activationOng, Pei-Shi ; Wang, Lingzhi ; Chia, Deborah Miao-Hui; Seah, Jolyn Yu-Xin; Kong, Li-Ren ; Thuya, Win-Lwin ; Chinnathambi, Arunachalam; Lau, Jie-Ying Amelia ; Wong, Andrea Li-Ann ; Yong, Wei-Peng ; Yang, Daiwen ; Ho, Paul Chi-Lui ; Sethi, Gautam ; Goh, Boon-Cher 
32018A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugsWong, A.L.-A ; Xiang, X; Ong, P.S ; Mitchell, E.Q.Y; Syn, N; Wee, I; Kumar, A.P ; Yong, W.P ; Sethi, G ; Goh, B.C ; Ho, P.C.-L ; Wang, L 
42016Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its developmentWang, L ; Khoa Phan, D.D; Zhang, J; Ong, P.-S ; Thuya, W.L ; Soo, R.A ; Wong, A.L.-A ; Yong, W.P ; Lee, S.C ; Ho, P.C.-L ; Sethi, G ; Goh, B.C 
527-Jul-2012Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcomeHoskins, J.M.; Ong, P.-S. ; Keku, T.O.; Galanko, J.A.; Martin, C.F.; Coleman, C.A.; Wolfe, M.; Sandler, R.S.; McLeod, H.L.
6Aug-2012Clinical therapeutics for phenylketonuriaKochhar, J.S.; Chan, S.Y. ; Ong, P.S. ; Kang, L. 
71-Oct-2003Current trends in modern pharmaceutical analysis for drug discoveryKoh, H.-L. ; Yau, W.-P. ; Ong, P.-S. ; Hegde, A.
8Jun-2011Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: Oxidative stress-independent and -dependent cytotoxic potentiationOng, P.-S. ; Chan, S.-Y. ; Ho, P.C. 
92016Judicious toggling of mTOR activity to combat insulin resistance and cancer: Current evidence and perspectivesOng, P.S ; Wang, L.Z; Dai, X; Tseng, S.H; Loo, S.J; Sethi, G 
1014-Feb-2012Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As 2O 3 and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsROng, P.-S. ; Chan, S.-Y. ; Ho, P.C. 
1128-Mar-2018Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signalingWang, Lingzhi ; Syn, Nicholas Li-Xun; Subhash, Vinod Vijay; Any, Yijia; Thuya, Win Lwin ; Cheow, Esther Sok Hwee ; Kong, Li Ren ; Yu, Fenggang ; Peethala, Praveen C. ; Wong, Andrea Li-Ann ; Laljibhai, Hirpara J. ; Chinnathambi, Arunachalam; Ong, Pei Shi ; Ho, Paul Chi-Lui ; Sethi, Gautam ; Yong, Wei Peng ; Goh, Boon Cher 
122014Quantification of the resveratrol analogs trans-2,3-dimethoxystilbene and trans-3,4-dimethoxystilbene in rat plasma: Application to pre-clinical pharmacokinetic studiesNg, S.Y; Cardullo, N; Yeo, S.C.M; Spatafora, C; Tringali, C; Ong, P.-S ; Lin, H.-S 
1318-Jan-2013Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic studyLin, H.-S. ; Sviripa, V.M.; Watt, D.S.; Liu, C.; Xiang, T.-X.; Anderson, B.D.; Ong, P.S. ; Ho, P.C. 
1420-Sep-2018Safety and Effectiveness of Azathioprine in Patients with Inflammatory Bowel Disease (IBD) in SingaporeFoo, Elston; Gan, Jia-min; Ong, Wan-chee; Chan, Webber ; Shim, Hang-hock ; Ong, Pei-Shi ; Lim, Teong-Guan 
15May-2012Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cellsOng, P.-S. ; Wang, X.-Q.; Lin, H.-S. ; Chan, S.-Y. ; Ho, P.C.